

## **Fundamental Patent related to Base Editing Granted in the US and China**

### **Kobe City, Japan -May 29, 2020-**

Bio Palette Co., Ltd. (Head Office: Nada-ku, Kobe City, Representative Director: Dr. Shoko Murase) has received licenses for several patent-pending base editing technologies of Kobe University, and has been cooperating with the university to acquire the rights for these patents. We are pleased to inform you that, among the patents filed internationally, patents have been granted in the United States and China to a basic invention related to base editing:

The US	Patent Number: 10,655,123	Issue Date: May 19, 2020
China	Patent Number: ZL2015 8 0023875.6	Issue Date: March 20, 2020

The recently granted patents seek to obtain the rights to the base editing technology (genome editing technology), which is the result of research by Professor Keiji Nishida and Professor Akihiko Kondo at Graduate School of Science, Technology and Innovation, Kobe University. Prior to the approval in the US and China, this technology had already been patented in Japan, Europe, Singapore and Hong Kong. Base editing technology, for which only two groups in the world, Kobe University and Harvard University, hold the basic patents, is a further development of genome editing technology called CRISPR/Cas9, and is capable of replacing a single base without breaking a double strand of DNA. Compared to conventional techniques, the major features of the system include precision and accuracy in editing, efficiency in breeding, and low cytotoxicity.

We are working on the development of innovative "Microbiome Therapeutics" by applying this unique base editing technology to the breeding/modification of microorganisms and administering bacterial preparations (so called "living medicine") optimized by gene editing. Aiming to be a leading company in the field of "Microbiome x Genome Editing", we have set the oral microbiome treatment as our first target, and are working on proof-of-concept studies in collaboration with external organizations for early commercialization. At the same time, we will promote the strategic and steady acquisition of rights for other related base editing patent applications for which we have received exclusive licenses from Kobe University, and further strengthen our patent portfolio that will serve as one of the most important business foundations for the global expansion of a leading-edge biotech start-up company.

Title of invention: Genomic Sequence Modification Method for Specifically Converting Nucleic Acid Bases of Targeted DNA Sequence, and Molecular Complex for Use in Same

Int'l application number: PCT/JP2015/056436

Int'l publication number: WO 2015/133554

Applicant: National University Corporation Kobe University

For inquiries regarding this release, please contact us at:

Bio Palette Co., Ltd.

Web: [www.biopalette.co.jp](http://www.biopalette.co.jp)

E-mail: [contact@biopalette.co.jp](mailto:contact@biopalette.co.jp)